TxCell names new CEO
This article was originally published in Scrip
Biotechnology company TxCell, which develops personalized cell-based immunotherapies using for chronic inflammatory and autoimmune diseases, has named Damian Marron chief executive officer. Prior to joining the Valbonne, France-based firm, Mr Marron was CEO of clinical stage biotechnology company Cytheris. Furthermore, from 2008-2012 he was CEO of Trophos. Under his tenure, Trophos spearheaded a group of major EU funded consortia of leading global experts and specialists working on a range of orphan diseases. Mr Marron succeeds Francois Meyer who has now been appointed executive chair of the TxCell's board of directors.
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.